A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).Afshin Dowlati, Luis Paz-Ares Rodríguez, Koichi Goto et al.|Journal of Clinical Oncology|2026Cited by 1